US 12,233,104 B2
Combination of an IL-2RBETA-selective agonist and a long-acting IL-15 agonist
Deborah H. Charych, Albany, CA (US); and Peter Benedict Kirk, Oxfordshire (GB)
Assigned to Nektar Therapeutics, San Francisco, CA (US)
Appl. No. 15/765,207
Filed by Nektar Therapeutics, San Francisco, CA (US)
PCT Filed Oct. 7, 2016, PCT No. PCT/US2016/056088
§ 371(c)(1), (2) Date Mar. 30, 2018,
PCT Pub. No. WO2017/062832, PCT Pub. Date Apr. 13, 2017.
Claims priority of provisional application 62/239,207, filed on Oct. 8, 2015.
Prior Publication US 2018/0296645 A1, Oct. 18, 2018
Int. Cl. A61K 38/20 (2006.01); A61K 47/60 (2017.01); A61P 35/00 (2006.01)
CPC A61K 38/2086 (2013.01) [A61K 38/2013 (2013.01); A61K 47/60 (2017.08); A61P 35/00 (2018.01)] 14 Claims
 
1. A method of treating a patient suffering from a cancer, the method comprising the steps of:
(a) administering to the patient an IL-2Rβ-activating amount of a long-acting, IL-2Rβ-selective agonist comprised of an IL-2 moiety covalently attached to a water-soluble polymer having the formula:

OG Complex Work Unit Chemistry
wherein each n is an integer from 3 to 4000, or pharmaceutically acceptable salts thereof; and
(b) administering an IL-15 receptor-activating amount of a long-acting IL-15 agonist comprised of an IL-15 protein covalently attached to at least one water-soluble polymer having a formula selected from:

OG Complex Work Unit Chemistry
and

OG Complex Work Unit Chemistry
wherein n for each formula is an integer from 3 to 4000, or pharmaceutically acceptable salts thereof.